ArticleDiabetology & metabolic syndrome2026
Association between serum bilirubin and diabetic retinopathy: results from the NHANES 1999-2018 and Mendelian randomization study.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAlthough serum bilirubin levels have been linked to diabetic retinopathy (DR), their causal role remains uncertain. We aimed to assess the relationship between bilirubin levels and diabetic retinopathy (DR) using both observational analyses and Mendelian randomization (MR) to infer causality.
methodsThe relationship between bilirubin levels and the risk of DR was analyzed using a cross-sectional study design and MR analysis, respectively. Data for the observational study were obtained from the 1999–2018 National Health and Nutrition Examination Survey (NHANES). Logistic regression was used to evaluate the association between bilirubin levels and DR. For MR, genetic instrumental variables (single-nucleotide polymorphisms, SNPs) associated with bilirubin levels and DR were obtained from the IEU Open genome-wide association studies (GWAS) project. The results of the inverse variance weighting (IVW) analysis were the primary results of the MR analysis. Odds ratio (OR) and 95% confidence interval (CI) were used to report results.
resultsA total of 8,274 diabetic patients from NHANES were included, of whom 1,242 (13.57%) had DR. Diabetic patients with serum total bilirubin > 10.3 µmol/L (vs. ≤ 10.3 µmol/L) had a lower prevalence of DR (OR = 0.77, 95% CI: 0.62–0.96). This association was observed in males (OR = 0.62, 95% CI: 0.47–0.81), individuals with chronic kidney disease (CKD) (OR = 0.72, 95% CI: 0.56–0.94), those with body mass index (BMI) ≥ 25 kg/m² (OR = 0.79, 95% CI: 0.63–1.00, P = 0.049), and those aged ≥ 65 years (OR = 0.76, 95% CI: 0.59–0.99, P = 0.043). MR analysis showed that genetically higher serum total bilirubin levels were associated with reduced risk of proliferative DR (PDR) [IVW OR = 0.910 (95% CI: 0.831–0.997), P = 0.044], whereas genetically predicted bilirubin was not related to non-proliferative DR (NPDR) (P = 0.893) or any DR (P = 0.481).
conclusionThis study support a potential causal relationship between higher serum total bilirubin levels and lower risk of PDR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.